[Featured Stock] Pharmicell Holds 80% Global Nucleoside Market Share... Moderna Vaccine Antibody Formation
[Asia Economy Reporter Hyungsoo Park] Pharmicell is showing strong performance. The news that the American pharmaceutical company Moderna Therapeutics has made progress in developing a novel coronavirus (COVID-19) vaccine appears to have influenced the stock price.
As of 11:35 AM on the 15th, Pharmicell is trading at 22,950 KRW, up 20.47% from the previous day.
Pharmicell is a domestic pharmaceutical company that produces 'nucleosides,' the main raw material needed for gene therapies including COVID-19 vaccines. It is known to hold more than 80% of the global market for diagnostic and pharmaceutical nucleosides.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Iran Delivers New Ceasefire Proposal to U.S.; U.S. Says "Not Sufficient to Conclude Negotiations"
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
According to major foreign media, the American pharmaceutical company Moderna succeeded in generating antibodies in all test subjects during the initial clinical trials for the COVID-19 vaccine development. Earlier, on March 16, Moderna began the world's first clinical trial administering a COVID-19 vaccine drug to humans. Moderna is now approaching Phase 3, the final stage before drug release.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
